mbq-167
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2023 (NCT06075810)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CDC42 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCn1c2ccccc2c2cc(-n3nncc3-c3ccccc3)ccc21- Mol. weight
- 338.41 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5290216 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06075810 | Phase 1 | Nov 9, 2023 | Department of Defense, MBQ Pharma |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2023 |
| MBQ Pharma | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1